Board & Advisors

Mr. Weinand is the former President, CEO and Chairman of the Board of Bayer Pharmaceuticals, AG and has 30 years of experience in senior executive roles with a number of pharmaceutical companies, including Sanofi, Otzuka and Pfizer. He has a demonstrated ability to recognize opportunity, create a vision and strategy, and mobilize organizations behind successful execution. Mr. Weinand has launched and marketed some of the industry’s most successful products, including Lipitor, Neurontin, Abilify, and Cipro.

Ms. Boudreau joins the Company’s Board of Directors after most recently serving as Chief Operating Officer for the Bill & Melinda Gates Medical Research Institute. Prior to that role, Ms. Boudreau served as CFO for biotech companies Proteostasis Therapeutics and FORMA Therapeutics. Previously, Ms. Boudreau spent 16 years at Novartis and Pfizer, serving in strategy and senior finance roles, including Global CFO, Oncology business unit, CFO US Corporate, VP Investor Relations, VP Finance, Customer Business Unit and Commercial Operations, and VP Finance Global R&D. She has contributed to successful product launches, driven sales growth and increased profitability, integrated mergers & acquisitions, and provided leadership across Finance, IT, HR, Strategic Sourcing, Facilities, and Innovation, Quality and Process improvement.

Barry Fishman has almost 25 years of experience as an entrepreneurial business leader, most recently as CEO of VIVO Cannabis Inc. (TSX:VIVO). Prior to joining VIVO, Mr. Fishman served as CEO of international specialty pharmaceutical company Merus Labs (TSX:MSL, NASDAQ:MSLI), through its 2017 acquisition by Norgine M.V. He also previously served as CEO of Teva Canada, a major affiliate of the world's largest generic drug-maker and began his pharmaceutical career at Eli Lilly Canada, where he served as Vice President of Marketing. Mr. Fishman has also recently served as an independent director on a number of high-profile boards, including Aurora Cannabis Inc. (NYSE, TSX: ACB) and Canopy Growth Corporation (TSX:WEED, NASDAQ:CGC). Mr. Fishman graduated from McGill University with a concentration in finance and went on to become a CPA while working for Deloitte in Southern California.

Ellen has served as Chief Business Officer of Werewolf Therapeutics, Inc. since August 2020. From October 2018 to July 2020, Ms. Lubman served as the Chief Business Officer at Impel NeuroPharma, Inc., a privately held biotechnology company focused on neurological diseases. Prior to Impel, she was the Vice President of External Science & Innovation at Forest Labs, from February 2014 until its acquisition by Actavis plc in July 2014, and served in the same role at Actavis through June 2018 during which time Actavis merged with and renamed itself Allergan plc. Prior to Allergan, Ms. Lubman held numerous executive and leadership roles at Kadmon Pharmaceuticals, Bristol Myers Squibb, Celtic Pharma Management, L.P., Robertson Stephens Investment Bank and Abbott Labs. She serves on the board of directors of GeneCentric Therapeutics as well as the Advisory Board of TMRW.org. Ms. Lubman also currently serves on the Scientific Advisory Board of the Daedalus Innovation Fund of Weill-Cornell and board of directors of Gilda’s Club of NYC and is the Southern California Chairwoman of Executive Women in BIO. Ms. Lubman earned her M.B.A. from Stanford Graduate School of Business with a focus on Global Management and her B.A. in Biology from Rutgers College.

Dr. Michael Ehlers has more than 20 years of experience in biopharmaceutical leadership and biomedical research. Currently CEO of Limelight Bio and CSO of Apple Tree Partners, Dr. Ehlers was previously Executive Vice President and Head of Research & Development at Biogen, one of the world’s oldest and largest biopharmaceutical companies. Prior to that, Dr. Ehlers was Senior Vice President of BioTherapeutics R&D and the Chief Scientific Officer for Neuroscience & Pain at Pfizer. He holds a BS in chemistry from the California Institute of Technology, and M.D. and Ph.D. degrees from the Johns Hopkins University School of Medicine.

Dr. Sidney H. Kennedy is Professor of Psychiatry at the University of Toronto, the Arthur Sommer Rotenberg Chair in Suicide and Depression Studies, and a Scientist at Li Ka Shing Knowledge Institute and Toronto Western Research Institute, Toronto, Canada. Dr. Kennedy is the lead investigator for a large depression biomarker initiative. He has published extensively on new drug evaluation, neuroimaging and neurostimulation therapies, personality factors in depression, antidepressant effects on sexual function and treatment guidelines for Major Depressive Disorder and Bipolar Disorder.Dr. Kennedy is the Immediate Past President of the International Society for Affective Disorders, former President of the Canadian College of Neuropsychopharmacology, and the founding chair of the Canadian Network for Mood and Anxiety Treatments (CANMAT). He has published more than 350 peer reviewed publications and 11 books on depression and related topics.

Dr. Hanlon is the founding Program Director for the University of Toronto Pain Medicine Residency. He is an Assistant Professor in the Department of Anesthesia and practices Anesthesia and Pain Medicine at St. Michael’s Hospital where he is Medical Director of the Chronic Pain Clinic. Dr. Hanlon is the founding Program Director for the University of Toronto Pain Medicine Residency. He is an Assistant Professor in the Department of Anesthesia and practices Anesthesia and Pain Medicine at St. Michael’s Hospital where he is Medical Director of the Chronic Pain Clinic.

Dr. Waisglass has been working in the Canadian medical cannabis industry, influencing physicians, researchers, and regulatory authorities, both domestically and abroad. In 2014 he became the seminal physician and medical director of Canadian Cannabis Clinics. Soon after Aurora Cannabis acquired CCC in 2016 he became their medical director. Prior to his service in the cannabis space he was a family doctor for almost 40 years.

Dr. Robert McMaster is a Forensic Psychiatrist with a diverse practice. He works at CAMH with patients who have severe and persistent mental health diagnoses. He is also the primary consulting psychiatrist to the Ontario Court of Justice on Finch Avenue, is actively involved in outreach psychiatry, and works within the field of addiction medicine. He completed his subspecialty training at the University of Toronto and is now a faculty member.

Sanjay Singhal is a Canadian Partner for 500 Startups Canada and the founder of Audiobooks.com. President of the Aquanta Group, A long-term inventor, entrepreneur, VC and angel investor. Sanjay assists startups and entrepreneurs achieve success by investing in them and using his own experiences to reduce risk and commonly made mistakes. Sanjay has an Undergraduate and Masters Degree in Electrical Engineering from the University of New Brunswick and the University of British Columbia as well as an MBA from Cornell University.

Executive Chairman of the KSS Group of Companies, and founder and former CEO of Kingsdale Advisors, Wes Hall has established himself as a preeminent leader in the Canadian business landscape. Canada’s leading newspaper, The Globe & Mail, has called him one of the nation’s “most influential powerbrokers” and Canadian Business magazine named him one of the “most powerful business people” in 2016. Wes has been the recipient of numerous awards and honors over the years, and currently serves as a director of SickKids Foundation, a board member of Pathways to Education and Toronto International Film Festival (TIFF), and was former Chairman of the Board of Difference Capital Financial.